Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Scinai Immunotherapeutics Refocuses on NanoAb Platform, Drops PC111 Option
TLDR
- Scinai refocuses on NanoAb and CDMO, securing $3.1M orders and pursuing $5M revenue for 2026, a strategic advantage.
- Scinai's option with PinCell expired Aug. 31, ending PC111 license; now it concentrates on NanoAb IL-17 programs and CDMO operations.
- Scinai's focus on NanoAb psoriasis program could bring new intradermal treatment, with €12M grant under evaluation in Poland.
- Scinai's decision to drop PC111 wasn't due to scientific failure, but to boost its NanoAb and CDMO businesses.
Impact - Why it Matters
This strategic refocusing by Scinai Immunotherapeutics is significant because it underscores the company's commitment to optimizing its R&D pipeline and strengthening its financial position. By prioritizing its NanoAb platform and CDMO business, Scinai aims to allocate resources more efficiently, potentially accelerating the development of its IL-17 programs for psoriasis and other indications. The decision to terminate the PC111 license, while not based on scientific failure, reflects a pragmatic approach to portfolio management in a competitive biotech landscape. For investors, this move could signal a more focused growth strategy, with the CDMO providing near-term revenue and the NanoAb platform offering long-term potential. The outcome of the €12 million grant evaluation and the pursuit of $5 million in CDMO revenue will be key indicators of the company's ability to execute its revised strategy.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company that combines immunology therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), has announced a strategic refocusing of its R&D portfolio following the expiration and termination of its option and license agreements with PinCell S.r.l. for PC111. The decision, effective August 31, was not driven by any negative scientific findings regarding PC111 but rather allows the company to concentrate its R&D resources on its NanoAb platform while preserving capital and management capacity for its CDMO business. Scinai is advancing two IL-17 programs within the NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. As of August 16, the company reported approximately $3.1 million in committed CDMO customer orders and continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities.
The company's decision to shift focus comes as it leverages its NanoAb platform, which is based on nanobodies licensed from the Max Planck Society. Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotech and pharma companies through facilities in Jerusalem and Yavne, Israel. The company's newsroom can be accessed at https://ibn.fm/SCNI for the latest updates. This strategic pivot is part of a broader effort to streamline operations and capitalize on its CDMO's revenue potential while advancing its most promising therapeutic candidates. Investors and industry watchers will be monitoring the progress of the NanoAb programs and the CDMO's performance in the coming quarters.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics Refocuses on NanoAb Platform, Drops PC111 Option
